Acute gastroenteritis is a risk factor for the development of disorders of gut-brain interaction in children
Abstract
ABSTRACT
Acute gastroenteritis (AGE) is the most common disease predisposing to the development of Disorders of Gut-Brain Interactions (DGBI) in adults (post-infection DGBI: PI-DGBI). There is paucity of data on incidence and risk factors for the development of PI-DGBI in children. Aim 1) assess whether AGE predisposes children to the development of PI-DGBI. 2) assess whether the severity of AGE is associated with the development of PI-DGBI. Methods: A prospective, controlled, cohort study. Children with recent AGE (cases) and siblings (controls) were followed for 6 months. We assessed DGBIs using a validated questionnaire (QPGS IV) per Rome criteria. Forty-nine cases and 55 controls were enrolled; 4 cases (8.1%) and 1 control (1.8%) had a previous diagnosis of DGBI. At 3-months, 10 cases (20.4%) were diagnosed with DGBI vs. 1 (1.8%) control (p = 0.00). Among children without a history of DGBI prior to the AGE, 6 (12.2%) cases vs. 0 control were diagnosed with DGBI (p = 0.01) at follow-up. At 6 months, 5 cases (1 lost to follow-up) vs. 0 control had persistent DGBI (p= 0.03). Severity of AGE was correlated with PI-DGBI (ρ = 0.707, p = 0.00). Conclusion: children with AGE are more likely to develop DGBIs compared to controls. AGE symptom severity is associated with PI-DGBI.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.